First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial-Reference-Cited by-同舟云学术

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Published:2016-07 Issue:7 Volume:17 Page:928-942
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Eichhorst Barbara,Fink Anna-Maria,Bahlo Jasmin,Busch Raymonde,Kovacs Gabor,Maurer Christian,Lange Elisabeth,Köppler Hubert,Kiehl Michael,Sökler Martin,Schlag Rudolf,Vehling-Kaiser Ursula,Köchling Georg,Plöger Christoph,Gregor Michael,Plesner Torben,Trneny Marek,Fischer Kirsten,Döhner Harmut,Kneba Michael,Wendtner Clemens-Martin,Klapper Wolfram,Kreuzer Karl-Anton,Stilgenbauer Stephan,Böttcher Sebastian,Hallek Michael

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Chronic lymphocytic leukemia in young (;Parikh;Haematologica,2014

2. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia;Keating;J Clin Oncol,2005

3. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia;Thompson;Blood,2016

4. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial;Fischer;Blood,2016

5. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase III trial;Hallek;Lancet,2010

Cited by 536 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting progression‐free survival from measurable residual disease in chronic lymphocytic leukemia;Clinical and Translational Science;2024-08

2. Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first‐line chemoimmunotherapy;Cancer Medicine;2024-08

3. Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia;Leukemia Research;2024-08

4. Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs;Cancers;2024-07-31

5. Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma;Leukemia & Lymphoma;2024-06-10